Varettoni Marzia, Corso Alessandro, Cocito Federica, Mangiacavalli Silvia, Pascutto Cristiana, Zappasodi Patrizia, Pica Gianmatteo, Lazzarino Mario
From Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy.
Medicine (Baltimore). 2010 Jul;89(4):211-216. doi: 10.1097/MD.0b013e3181e763be.
To assess whether the pattern of presentation and the outcome of monoclonal gammopathy of undetermined significance (MGUS) have changed over the last 3 decades, we evaluated 1400 patients, divided into 3 groups: group I (1975-1987), group II (1988-1997), and group III (1998-2007). We observed a significant increase in age (p = 0.001), IgM and biclonal MGUS (p = 0.003), hemoglobin (p < 0.0001), and albumin (p = 0.0001), and a significant reduction of monoclonal (M)-protein concentration (p < 0.0001), percentage of bone marrow plasma cells (p < 0.0001), and beta2-microglobulin (p = 0.0001) over the 3 decades. The proportion of patients with M-protein <1.5 g/dL was significantly higher in group III (66%) than in group II (44%) and group I (26%) (p < 0.0001). By Kaplan-Meier analysis, group III had a significantly lower 5-year probability of transformation (5%) compared to group II (12%) and group I (22%) (p = 0.003). Patients with M-protein <1.5 g/dL had the same life expectancy as the general population (standardized mortality ratio 1.09; p = 0.41). In conclusion, we found that the pattern of presentation of MGUS has changed over time and now includes a higher proportion of patients with more favorable presenting features and probably a better outcome compared to patients presenting in the past. This changing scenario calls for revising the current concepts of the clinical significance of MGUS and the management of patients.
为评估意义未明的单克隆丙种球蛋白病(MGUS)的临床表现模式及预后在过去30年中是否发生了变化,我们对1400例患者进行了评估,这些患者被分为3组:第一组(1975 - 1987年)、第二组(1988 - 1997年)和第三组(1998 - 2007年)。我们观察到在这30年中,年龄(p = 0.001)、IgM和双克隆MGUS(p = 0.003)、血红蛋白(p < 0.0001)和白蛋白(p = 0.0001)显著增加,而单克隆(M)蛋白浓度(p < 0.0001)、骨髓浆细胞百分比(p < 0.0001)和β2-微球蛋白(p = 0.0001)显著降低。M蛋白<1.5 g/dL的患者比例在第三组(66%)显著高于第二组(44%)和第一组(26%)(p < 0.0001)。通过Kaplan-Meier分析,与第二组(12%)和第一组(22%)相比,第三组的5年转化概率显著更低(5%)(p = 0.003)。M蛋白<1.5 g/dL的患者与普通人群的预期寿命相同(标准化死亡率1.09;p = 0.41)。总之,我们发现MGUS的临床表现模式随时间发生了变化,现在与过去就诊的患者相比,具有更有利表现特征的患者比例更高,可能预后也更好。这种不断变化的情况要求修订当前关于MGUS临床意义和患者管理的概念。